BIIB
Price
$133.25
Change
-$0.96 (-0.72%)
Updated
Jul 14, 04:51 PM (EDT)
Capitalization
31.34B
17 days until earnings call
JNJ
Price
$156.12
Change
-$0.78 (-0.50%)
Updated
Jul 14, 01:47 PM (EDT)
Capitalization
380.22B
2 days until earnings call
Interact to see
Advertisement

BIIB vs JNJ

Header iconBIIB vs JNJ Comparison
Open Charts BIIB vs JNJBanner chart's image
Biogen
Price$133.25
Change-$0.96 (-0.72%)
Volume$858
Capitalization31.34B
Johnson & Johnson
Price$156.12
Change-$0.78 (-0.50%)
Volume$12.84K
Capitalization380.22B
BIIB vs JNJ Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. JNJ commentary
Jul 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and JNJ is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2025
Stock price -- (BIIB: $134.21 vs. JNJ: $156.90)
Brand notoriety: BIIB and JNJ are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 76% vs. JNJ: 104%
Market capitalization -- BIIB: $31.34B vs. JNJ: $380.22B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. JNJ’s [@Pharmaceuticals: Major] market capitalization is $380.22B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileJNJ’s FA Score has 2 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • JNJ’s FA Score: 2 green, 3 red.
According to our system of comparison, JNJ is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while JNJ’s TA Score has 8 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 2 bearish.
  • JNJ’s TA Score: 8 bullish, 2 bearish.
According to our system of comparison, JNJ is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +1.01% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +0.57% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.61%. For the same industry, the average monthly price growth was +0.54%, and the average quarterly price growth was +10.72%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

JNJ is expected to report earnings on Oct 21, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.61% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JNJ($380B) has a higher market cap than BIIB($31.3B). JNJ has higher P/E ratio than BIIB: JNJ (30.34) vs BIIB (26.95). JNJ YTD gains are higher at: 10.297 vs. BIIB (-12.235). JNJ has higher annual earnings (EBITDA): 23.3B vs. BIIB (2.04B). JNJ has more cash in the bank: 22.9B vs. BIIB (1.05B). BIIB has less debt than JNJ: BIIB (7.34B) vs JNJ (29.3B). JNJ has higher revenues than BIIB: JNJ (85.2B) vs BIIB (9.84B).
BIIBJNJBIIB / JNJ
Capitalization31.3B380B8%
EBITDA2.04B23.3B9%
Gain YTD-12.23510.297-119%
P/E Ratio26.9530.3489%
Revenue9.84B85.2B12%
Total Cash1.05B22.9B5%
Total Debt7.34B29.3B25%
FUNDAMENTALS RATINGS
BIIB vs JNJ: Fundamental Ratings
BIIB
JNJ
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
10038
SMR RATING
1..100
7233
PRICE GROWTH RATING
1..100
6037
P/E GROWTH RATING
1..100
9779
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JNJ's Valuation (18) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (88) in the Biotechnology industry. This means that JNJ’s stock grew significantly faster than BIIB’s over the last 12 months.

JNJ's Profit vs Risk Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (100) in the Biotechnology industry. This means that JNJ’s stock grew somewhat faster than BIIB’s over the last 12 months.

JNJ's SMR Rating (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (72) in the Biotechnology industry. This means that JNJ’s stock grew somewhat faster than BIIB’s over the last 12 months.

JNJ's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as BIIB (60) in the Biotechnology industry. This means that JNJ’s stock grew similarly to BIIB’s over the last 12 months.

JNJ's P/E Growth Rating (79) in the Pharmaceuticals Major industry is in the same range as BIIB (97) in the Biotechnology industry. This means that JNJ’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBJNJ
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
42%
Momentum
ODDS (%)
Bullish Trend 4 days ago
51%
Bullish Trend 4 days ago
36%
MACD
ODDS (%)
Bullish Trend 4 days ago
49%
Bullish Trend 4 days ago
33%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
54%
Bullish Trend 4 days ago
40%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
55%
Bullish Trend 4 days ago
38%
Advances
ODDS (%)
Bullish Trend 13 days ago
54%
Bullish Trend 5 days ago
39%
Declines
ODDS (%)
Bearish Trend 8 days ago
70%
Bearish Trend 25 days ago
43%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
54%
Bullish Trend 4 days ago
47%
Aroon
ODDS (%)
Bullish Trend 4 days ago
32%
Bullish Trend 4 days ago
32%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
THYF52.30N/A
N/A
T. Rowe Price U.S. High Yield ETF
EEM48.26-0.16
-0.33%
iShares MSCI Emerging Markets ETF
JOET40.74-0.28
-0.68%
Virtus Terranova US Quality Momentum ETF
NXTE35.11-0.34
-0.95%
AXS Green Alpha ETF
MAKX47.29-0.67
-1.40%
ProShares S&P Kensho Smart Factories ETF